Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PROMUS Element(TM) China Post-Approval Study

Trial Profile

PROMUS Element(TM) China Post-Approval Study

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 10 Mar 2017

At a glance

  • Drugs Everolimus (Primary)
  • Indications Coronary artery disease
  • Focus Therapeutic Use
  • Acronyms PEChina
  • Sponsors Boston Scientific Corporation
  • Most Recent Events

    • 07 Mar 2017 Status changed from recruiting to active, no longer recruiting.
    • 02 Sep 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
    • 11 Sep 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top